On December 20, 2024, the FDA granted accelerated approval to the combination of encorafenib (Braftovi), cetuximab (Erbitux), ...

Sacituzumab govitecan, currently indicated in triple-negative breast cancer (TNBC), is undergoing evaluation in NSCLC. In ...

The antibody-drug conjugate showed a higher objective response rate but failed to meet the primary OS endpoint in patients ...

Sacituzumab govitecan is under clinical development by Gilead Sciences and currently in Phase II for Esophageal Cancer.

Sacituzumab govitecan is under clinical development by Gilead Sciences and currently in Phase II for Hepatocellular Carcinoma.

This first approval of Dato-DXd is a boost to Daiichi Sankyo and AZ, given that the path to market for the drug's second ...

rohit sharma ki wife Everest Medicines' Phase 3 Clinical Trial Application for Sacituzumab Govitecan Approved Pharmaceutical and Health Industry Weekly Report (September 23-September 27) [Two Sessions ...

INR:5297. bet365 founded The latest clinical progress of CRISPR/Cas9 gene editing therapy Everest Medicines' Phase 3 Clinical Trial Application for Sacituzumab Gov ...

The FDA has granted breakthrough therapy designation Trodelvy for adults with extensive-stage small cell lung cancer who ...

Sacituzumab govitecan failed to improve overall survival in the EVOKE-01 trial, but was well tolerated with no new safety signals. Comprehensive genomic profiling is crucial to address testing ...

President Donald Trump talks to the media at a public press event following the RNC debate in Houston, Texas in February 2016. Picture: Stock_photo_world/Shutterstock ...

Gilead Sciences GILD announced that its first-in-class Trop-2-directed antibody-drug conjugate, Trodelvy (sacituzumab ...